CA3237660A1 - Anti-tau antibody compositions, dosage forms, and methods - Google Patents

Anti-tau antibody compositions, dosage forms, and methods Download PDF

Info

Publication number
CA3237660A1
CA3237660A1 CA3237660A CA3237660A CA3237660A1 CA 3237660 A1 CA3237660 A1 CA 3237660A1 CA 3237660 A CA3237660 A CA 3237660A CA 3237660 A CA3237660 A CA 3237660A CA 3237660 A1 CA3237660 A1 CA 3237660A1
Authority
CA
Canada
Prior art keywords
antibody
human subject
tauopathy
tau
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237660A
Other languages
English (en)
French (fr)
Inventor
Larisa Reyderman
Sumit RAWAL
Kristin Ruth WILDSMITH
Jin Zhou
Pau Aceves BALDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA3237660A1 publication Critical patent/CA3237660A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3237660A 2021-11-03 2022-11-03 Anti-tau antibody compositions, dosage forms, and methods Pending CA3237660A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275045P 2021-11-03 2021-11-03
US63/275,045 2021-11-03
US202163290278P 2021-12-16 2021-12-16
US63/290,278 2021-12-16
US202263316582P 2022-03-04 2022-03-04
US202263316616P 2022-03-04 2022-03-04
US63/316,582 2022-03-04
US63/316,616 2022-03-04
PCT/IB2022/060604 WO2023079485A1 (en) 2021-11-03 2022-11-03 Anti-tau antibody compositions, dosage forms, and methods

Publications (1)

Publication Number Publication Date
CA3237660A1 true CA3237660A1 (en) 2023-05-11

Family

ID=84360026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237660A Pending CA3237660A1 (en) 2021-11-03 2022-11-03 Anti-tau antibody compositions, dosage forms, and methods

Country Status (9)

Country Link
US (1) US20260159575A1 (enExample)
EP (1) EP4426336A1 (enExample)
JP (1) JP2024540226A (enExample)
KR (1) KR20240118915A (enExample)
AU (1) AU2022381556A1 (enExample)
CA (1) CA3237660A1 (enExample)
MX (1) MX2024005430A (enExample)
TW (1) TW202334201A (enExample)
WO (1) WO2023079485A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
CN117946264B (zh) * 2024-03-21 2024-06-04 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其应用
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Also Published As

Publication number Publication date
KR20240118915A (ko) 2024-08-05
WO2023079485A1 (en) 2023-05-11
TW202334201A (zh) 2023-09-01
MX2024005430A (es) 2024-05-21
JP2024540226A (ja) 2024-10-31
EP4426336A1 (en) 2024-09-11
AU2022381556A1 (en) 2024-05-02
US20260159575A1 (en) 2026-06-11

Similar Documents

Publication Publication Date Title
EP4426336A1 (en) Anti-tau antibody compositions, dosage forms, and methods
Qureshi et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
EP2764022B1 (en) Phosphospecific antibodies recognising tau
US20220402979A1 (en) Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
US9745371B2 (en) Anti-PHF-tau antibodies and their uses
JP2025131566A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用
CA3179914A1 (en) Anti-phf-tau antibodies and uses thereof
WO2023111618A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202339794A (zh) 使用ｐ—ｔａｕ１８１水平之治療方法
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
TW202313111A (zh) 治療阿茲海默症之方法
CN118215497A (zh) 抗tau抗体组合物、剂型和方法
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
Buracchio RE: FDA-2024-N-1869 Response for BLA 761248 Dear Dr. Buracchio
KR20240067001A (ko) 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
WO2025064824A1 (en) Methods for treating alzheimer's disease
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025